Marshall Wace’s Adicet Bio ACET Stock Holding History

Marshall Wace’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$687K	Buy	+79,488	New	+$626K	﹤0.01%	2381
2025 Q4	–	Sell	-3,233	Closed	-$41.9K	–	2905
2025 Q3	$41.9K	Buy	+3,233	New	+$38.1K	﹤0.01%	2739
2025 Q1	–	Sell	-2,519	Closed	-$38.7K	–	2579
2024 Q4	$38.7K	Sell	2,519 -6,556	-72%	-$124K	﹤0.01%	2496
2024 Q3	$209K	Buy	9,075 +6,867	+311%	+$154K	﹤0.01%	2282
2024 Q2	$42.7K	Buy	+2,208	New	+$59.2K	﹤0.01%	2453
2023 Q4	–	Sell	-9,532	Closed	-$209K	–	2116
2023 Q3	$209K	Buy	+9,532	New	+$337K	﹤0.01%	1965
2023 Q2	–	Sell	-1,223	Closed	-$113K	–	2405
2023 Q1	$113K	Buy	+1,223	New	+$153K	﹤0.01%	2492
2022 Q4	–	Sell	-5,284	Closed	-$1.2M	–	2879
2022 Q3	$1.2M	Buy	5,284 +3,272	+163%	+$831K	﹤0.01%	2312
2022 Q2	$470K	Buy	+2,012	New	+$442K	﹤0.01%	2814
2021 Q3	–	Sell	-784	Closed	-$129K	–	2963
2021 Q2	$129K	Buy	+784	New	+$160K	﹤0.01%	2516
2019 Q2	–	Sell	-28	Closed	-$21K	–	1296
2019 Q1	$21K	Buy	+28	New	+$25.4K	﹤0.01%	1625

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Marshall Wace's ACET Position: Q2 2026 in Review

Marshall Wace opened a new position in Adicet Bio (ACET) in Q2 2026: 79,488 shares worth $687K. The stake represents ﹤0.01% of the portfolio and ranks #2381 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ACET as recently as Q3 2025.

Marshall Wace first reported a position in ACET in Q1 2019 and has held it in 11 quarters since. The position peaked at $1.2M in Q3 2022. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

Marshall Wace held 79,488 shares of Adicet Bio worth $687K as of Q2 2026.
Adicet Bio was a new Marshall Wace position in Q2 2026.
Adicet Bio made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2381 holding.
Marshall Wace first reported a position in Adicet Bio in Q1 2019 and has held it in 11 quarters since.
Marshall Wace's Adicet Bio position peaked at $1.2M in Q3 2022.
56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.